| DIRECT COMPETITOR COMPARISON | |
| PARD | BMY | IMGN | SNY | Industry | | Market Cap: | 60.83M | 51.03B | 456.48M | 104.11B | 101.56M | | Employees: | 59 | 35,000 | 210 | 98,213 | 63 | | Qtrly Rev Growth (yoy): | N/A | 4.40% | -49.40% | 8.50% | 19.10% | | Revenue (ttm): | N/A | 21.14B | 24.96M | N/A | 13.84M | | Gross Margin (ttm): | N/A | 72.39% | -85.22% | 75.20% | 65.67% | | EBITDA (ttm): | -41.29M | 6.32B | -28.47M | N/A | -11.86M | | Oper Margins (ttm): | N/A | 26.65% | -134.15% | N/A | -149.46% | | Net Income (ttm): | -46.99M | 3.79B | -34.92M | N/A | N/A | | EPS (ttm): | -1.354 | 1.933 | -0.663 | N/A | -0.31 | | P/E (ttm): | N/A | 13.33 | N/A | N/A | 17.46 | | PEG (5 yr expected): | N/A | 5.09 | N/A | 2.49 | 1.35 | | P/S (ttm): | N/A | 2.41 | 18.36 | N/A | 10.21 |
|
| BMY = Bristol-Myers Squibb Co. | | IMGN = Immunogen Inc. | | SNY = Sanofi-Aventis | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.42 | 0.12% | 58.12B | 12.52 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 52.24 | 0.15% | 15.11B | 17.48 | | Genzyme Corp. | GENZ | 48.50 | 0.62% | 12.87B | 27.65 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.00 | -0.02% | 38.70B | 16.63 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.17 | 0.68% | 9.30B | 1064.69 | | Teva Pharmaceutical Industries Limited | TEVA | 55.94 | -0.07% | 49.28B | 51.18 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.91 | 0.28% | 4.24B | 20.57 | | King Pharmaceuticals Inc. | KG | 12.14 | -0.82% | 3.01B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.74 | 0.00% | 5.73B | 114.97 | | Pfizer Inc. | PFE | 18.60 | 0.11% | 150.09B | 15.45 | | Johnson & Johnson | JNJ | 64.70 | 0.20% | 178.51B | 14.13 | | GlaxoSmithKline plc | GSK | 42.29 | 0.48% | 107.21B | 13.87 | | Sanofi-Aventis | SNY | 39.87 | 0.43% | 104.11B | N/A | | Novartis AG | NVS | 54.84 | 0.44% | 124.55B | 16.42 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.20 | 0.93% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 0.89% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.15 | 0.11% | 83.76B | 14.67 | | Bristol-Myers Squibb Co. | BMY | 25.76 | 0.23% | 51.03B | 13.33 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BMY | | Biggest changes in NYSE short interest
Thu 5:10pm -
at Reuters | | • | BMY | | Obama's Health-Care Reform "Quite Positive" for Big Pharma, Managed Care Stocks
Thu 2:58pm -
TechTicker | | • | SNY | | SEC: Men Made 'Illicit Profits' in Sanofi-Chattem Deal
Thu 1:18pm -
at The Wall Street Journal Online | | • | SNY | | Why Investing's Better in Bhutan
Thu 10:50am -
at Motley Fool | | • | BMY | | European Health Care Approvals And Partnership With Drug Giant Novartis Cements This Stocks Rating As A Good Buy, According To Senior Portfolio Manager
Thu 9:37am -
Wall Street Transcript | | • | BMY | | 5 Stocks That Give the Gift of Dividend Growth
Thu 9:07am -
at Seeking Alpha | | • | BMY | | Wall Street Breakfast: Must-Know News
Thu 7:19am -
at Seeking Alpha | | • | BMY | | Cramer's Stop Trading! Why the Housing News Is Good (12/23/09)
Thu 6:58am -
at Seeking Alpha | | • | BMY | | BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financi
Thu 6:07am -
EDGAR Online | | • | BMY | | Bristol-Myers Cuts 2009 Outlook
Thu 4:16am -
Zacks.com | | • | SNY | | Sanofi-Aventis Reaches over the Counter
Thu 4:06am -
at Seeking Alpha | | • | SNY | | Sanofi Pulls the Plug on Two Drugs: Biotech's Latest Mishaps
Thu 3:15am -
at Seeking Alpha | | • | SNY | | AZ and Forest tie up to buy Novexel
Wed 7:00pm -
at FT.com | | • | BMY | | Bristol-Myers spent $953K lobbying gov't in 3Q
Wed 6:35pm -
AP | | • | SNY | | SEC charges two men with insider trading in Sanofi-Chattem deal
Wed 6:05pm -
at bizjournals.com | | • | SNY | | FDA Licenses New Influenza Vaccine Designed Specifically for People 65 Years of Age and Older
Wed 5:25pm -
PR Newswire | | • | BMY | | BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia
Wed 5:19pm -
EDGAR Online | | • | IMGN | | ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & Quality
Thu, Dec 17 -
Business Wire | | • | IMGN | | Lightning Round OT: Tekelec, Jazz Pharma and More
Wed, Dec 16 -
at CNBC | | • | IMGN | | UPDATE - Roche restarts Phase III Avastin clinical trial
Mon, Dec 14 -
at Reuters | | • | IMGN | | Roche-ImmunoGen to Start New T-DM1 Clinical Trials
Mon, Dec 14 -
at TheStreet.com | | • | IMGN | | Roche-ImmunoGen to Start T-DM1 Trials
Mon, Dec 14 -
at TheStreet.com | | | All Headlines for these symbols... |
|
|
|
0.51% Nasdaq 
0.06 (3.33%) 
Competitors
